Screening chemical inhibitors for alpha-amylase from leaves extracts of Murraya koenigii (Linn.) and Aegle marmelos L
Aqueous leaves extracts of and were prepared and effect of the extracts on inhibiting alpha-amylase playing essential roles on converting starch into glucose have been examined using assays. Alpha amylase inhibitory assay was used to asses the antidiabetic activity of the extracts. Gas chromatograph...
Gespeichert in:
Veröffentlicht in: | Journal of complementary & integrative medicine 2020-08, Vol.18 (1), p.51-57 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Aqueous leaves extracts of
and
were prepared and effect of the extracts on inhibiting alpha-amylase playing essential roles on converting starch into glucose have been examined using
assays.
Alpha amylase inhibitory assay was used to asses the
antidiabetic activity of the extracts. Gas chromatography-mass spectrometry (GC-MS) analysis was performed to identify the volatile molecules of the extracts. Identified molecule were converted as ligand and docked against human pancreatic
-amylase (0.95 Å; PDB ID: 5U3A) using Autodock tool.
The data analyzes suggested that the alpha-amylase inhibition potential of the extract obtained from
was stronger than that of the
at low concentrations (1 mg/mL). The phytochemicals present in both the plant extracts were identified by using their respective GC-MS data and the data analyzes revealed that the extracts of
and
seemed to consist of about 20 and 24 diverse chemical molecules, respectively. Through the molecular docking studies, azulene of
and hydroxycyclodecadiene of
showed higher binding affinity on alpha-amylase.
Concentration-dependent alpha-amylase inhibition effects of the extracts were observed and
contains more alpha-amylase inhibitory effects due to the presence of azulene. This is primary lead to find out the better anti diabetic natural based drug to the society after clinical trial. |
---|---|
ISSN: | 2194-6329 1553-3840 |
DOI: | 10.1515/jcim-2019-0345 |